Haemonetics (NYSE:HAE) Reaches New 1-Year High – Still a Buy?

Shares of Haemonetics Corporation (NYSE:HAE) hit a new 52-week high during mid-day trading on Friday . The company traded as high as $85.23 and last traded at $84.81, with a volume of 82373 shares. The stock had previously closed at $83.81.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Needham & Company LLC raised their price objective on Haemonetics from $68.00 to $78.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. JPMorgan Chase & Co. restated a “neutral” rating and set a $62.00 price target (down previously from $85.00) on shares of Haemonetics in a research note on Friday, August 8th. Barrington Research lifted their target price on shares of Haemonetics from $86.00 to $90.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. Weiss Ratings restated a “hold (c-)” rating on shares of Haemonetics in a research note on Monday. Finally, Mizuho lowered their price objective on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average price target of $79.70.

Haemonetics Price Performance

The firm has a market capitalization of $3.97 billion, a PE ratio of 24.82, a P/E/G ratio of 1.47 and a beta of 0.30. The firm’s fifty day moving average price is $61.12 and its 200 day moving average price is $63.74. The company has a current ratio of 1.64, a quick ratio of 1.03 and a debt-to-equity ratio of 1.08.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $327.32 million during the quarter, compared to analysts’ expectations of $311.61 million. During the same quarter last year, the company posted $1.12 earnings per share. The firm’s revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. As a group, equities analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of HAE. Quarry LP grew its stake in shares of Haemonetics by 63.4% during the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 192 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock worth $31,000 after buying an additional 396 shares in the last quarter. GAMMA Investing LLC grew its position in Haemonetics by 59.4% during the second quarter. GAMMA Investing LLC now owns 443 shares of the medical instruments supplier’s stock valued at $33,000 after buying an additional 165 shares during the period. Versant Capital Management Inc increased its holdings in Haemonetics by 216.4% in the third quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 567 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its position in shares of Haemonetics by 20,925.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 841 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 837 shares during the period. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.